Health Canada approves Celltrion’s Omlyclo™ (CT-P39), the first and only omalizumab biosimilar in Canada
Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...
punjabnewsexpress2d
Celltrion wins approval for allergic asthma treatment biosimilar in Canada
South Korea's pharmaceutical giant Celltrion on Monday said that it has received approval from Canadian health authorities for a biosimilar treatment for allergic asthma.
Celltrion secures Canada's approval for Xolair biosimilar Omlyclo
South Korean biopharmaceutical firm Celltrion said Monday that it has received approval from Health Canada for Omlyclo, its omalizumab biosimilar referencing Xolair, designed to treat allergic asthma ...
The Korea Herald14d
Samsung reveals new leadership in foundry push
Start your day with a roundup of key stories from The Korea Herald with news and comment on all that’s happening in Korea. By Jie Ye-eun Published : Nov. 27, 2024 - 15:02 ...
New York Post22d
Suspected madman stabber has long criminal history — and was released from NYC jail just one month before deadly spree
The suspected madman behind a deadly stabbing spree in Manhattan Monday has a long criminal history — and had just walked free from Rikers Island a month before the terrifying attacks, The Post ...
Yahoo Finance27d
Celltrion Announces the Acquisition of iQone Healthcare Switzerland, Further Building Its Expertise and Foothold in Europe
INCHEON, South Korea, November 14, 2024--(BUSINESS WIRE)--Celltrion (KRX:068270), a global biopharmaceutical leader, announced its acquisition of iQone Healthcare Switzerland, a specialty ...
BioSpace28d
Celltrion Announces the Acquisition of iQone Healthcare Switzerland, Further Building Its Expertise and Foothold in Europe
Celltrion announces acquisition of iQone Healthcare Switzerland, accelerating direct commercialization of its biosimilars in the European region The acquisition strengthens Celltrion’s presence in ...